Advertisement

Topics

Companies Related to "Data Aquisition for Optimization of Coronary Artery Disease Algorithm" [Most Relevant Company Matches] RSS

15:02 EST 16th December 2018 | BioPortfolio

Here are the most relevant search results for "Data Aquisition for Optimization of Coronary Artery Disease Algorithm" found in our extensive corporate database of over 50,000 company records.

Showing "Data Aquisition Optimization Coronary Artery Disease Algorithm" Companies 1–25 of 5,100+

Extremely Relevant

PlaqueTec Ltd.

PlaqueTec offers a first-of-its-kind catheter technology for cardiologists to routinely assess inflammation in the coronary artery, and better understand residual inflammatory risk. It has been proven to detect inflammatory molecules across the site of coronary artery disease (CAD), and can discriminate between patients with greater and lesser levels of co...


PLC Systems

PLC is a global leader in the development of products for performing a revolutionary new surgical procedure known as transmyocardial revascularization (TMR). TMR offers a completely new medical treatment option for patients who suffer from severe coronary artery disease. Coronary artery disease is the leading cause of death in the United States. Working with leading researchers and premier heart...

Rcadia Medical Imaging Ltd.

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The COR Analyzer...


Relevant

Rcadia Medical Imaging

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated, real-time analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The C...

Rcadia Medical Imaging, Ltd.

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated, real-time analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The C...

Cappella, Inc.

Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD), specifically bifurcation disease. Cappella’s initial product, the Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses on treating...

Cappella Inc.

Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. Cappella's initial product, the Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses on treating the sidebranch of diseased coronary ...

Foxhollow Technologies

An estimated 12 million people in the U.S. alone have peripheral arterial disease (PAD). At least 40% of them also suffer from coronary artery disease (CAD). FoxHollow recently launched the SilverHawk® Plaque Excision System, a device that removes the plaque that commonly blocks arteries and interrupts blood flow. Unlike stenting and other methods of opening the artery, the SilverHawk removes the...

EPIXMedical Incorporated

EPIX's goal is to transform the management and diagnosis of vascular disease through the development of targeted MRI contrast agents. Based on its core, proprietary technology, EPIX is advancing its pipeline of products such as MS-325, the Company's lead MRI contrast agent currently in Phase III trials. MS-325 is also in development to help diagnose coronary artery disease, breast cancer, female s...

EPIX Medical Incorporated

Based on its core, proprietary technology, EPIX is advancing its pipeline of products such as MS-325, the Company's lead MRI contrast agent currently in Phase III trials. MS-325 is also in development to help diagnose coronary artery disease, breast cancer, female sexual arousal dysfunction, atherosclerosis and myocardial perfusion. In addition to MS-325, EPIX's pipeline includes a new class of MR...

HeartFlow Inc.

HeartFlow Inc. is a personalized medical technology company dedicated to transforming the way cardiovascular disease is managed. Committed to improving outcomes, reducing costs and creating a better patient experience, HeartFlow’s goal is to provide healthcare professionals with actionable knowledge about each patient by combining best-in-class, non-i...

Pathway Medical Technologies Inc.

Pathway Medical Technologies, Inc. (Pathway), located in Redmond, Washington was founded in 1998 to design, develop and manufacture innovative medical devices intended for the treatment of arterial disease. The company’s initial focus is on peripheral artery disease (PAD).According to the American Heart Association, peripheral artery disease affects 8 – 12 million in the U.S. PAD prevalence in...

Cappella Medical Devices Limited

Cappella, Inc. develops novel solutions for the treatment of complex coronary artery disease (CAD) - specifically bifurcation disease. Cappella’s Sideguard® coronary sidebranch technology offers interventional cardiologists a straightforward, effective, solution that focuses on treating the sidebranch of diseased coronary arteries first, rather tha...

HeartFlow, Inc.

HeartFlow, Inc., based in Redwood City, Calif., is pioneering technology designed to help physicians noninvasively diagnose coronary artery disease, improve patient outcomes and reduce health care costs. For more information visit www.heartflow.com.

Cappella Medical Devices Ltd

Cappella, Inc. is a medical device company that develops novel solutions for the treatment of complex coronary artery disease (CAD) focused on protecting the coronary sidebranch arteries. Cappella’s Sideguard® coronary sidebranch technology offers interventional cardiologists a straightforward, effective, and easy to use solution that preserves the ...

Squeeze Report Inc.

The short data is downloaded from Finras’ Reg SHO Daily Files and the quote data is downloaded from Quote Media daily. The Estimated Shares Shorted is the amount of shares our algorithm estimates is still short. The Estimated Shares Covered is the amount of shares our algorithm estimates has been covered. The Estimated Shares Still Short is the differ...

CathWorks

CathWorks is a medical technology company focused on applying its advanced computational science platform to optimize PCI therapy decisions and elevate coronary angiography from visual assessment to an objective FFR-based decision-making tool for physicians. FFR-guided PCI decision-making is proven to provide significant clinical benefits for patients with...

Cappella Medical Devices, Ltd.

Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. Cappella’s initial product, the Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses...

Ischemix

Ischemix is a privately-held drug discovery company with a portfolio of small molecule therapeutic compounds. The first of these compounds is targeted to reduce cell death and organ damage due to initial interruption and subsequent resumption of blood flow associated with cardiac surgeries and interventional procedures such as percutaneous coronary interve...

BridgePoint Medical, Inc.

BridgePoint Medical, Inc. is a privately held company established in 2006 to design, develop and commercialize new technologies and techniques to treat challenging coronary artery disease. Investors include New Enterprise Associates, Polaris Venture Partners, Foundation Medical Partners and Michael Berman.

Novogen

Novogen's business is in the most pressing area facing medicine in the modern era - that of degenerative diseases and disorders. Cancer Heart disease (stroke, hypertension, coronary artery disease) Osteoporosis Rheumatoid arthritis Inflammatory Bowel Disease (ulcerative colitis, Crohn's Disease) Neurological diseases (Parkinson's Disease, motor neurone disease) Autoimmune diseases (m...

Cardica

Cardica designs and manufactures proprietary automated anastomotic systems used by surgeons to perform coronary artery bypass graft (CABG) surgery. In CABG procedures, veins or arteries are used to construct alternative conduits to restore blood flow beyond narrowed or occluded portions of coronary arteries, "bypassing" the narrowed or occluded portion of the artery that is impairing blood flow to...

REVA Medical, Inc.

REVA is dedicated to developing minimally invasive medical devices that leverage the Company's proprietary biomaterial and stent technologies to improve the treatment of disease. Guided by a management team and scientific advisors with extensive product development and clinical interventional cardiology experience, REVA's initial focus is the development and eventual commercialization of...

Magna-Lab

Magna-Lab Inc. is the developer of products that are designed to make MRI technology more effective for the detection and diagnosis of Coronary Artery Disease. The products are non-invasive or minimally-invasive disposable medical devices that permit imaging of the major vessels of the heart and may identify the nature of blockages which is important to determining the appropriate treatment. The C...

FluoroPharma, Inc.

FluoroPharma, Inc., a privately-held molecular imaging company headquartered in Boston MA, engages in the discovery, development and commercialization of proprietary diagnostic imaging products for the PET market. The company's initial focus is the advancement of three imaging agents -- CardioPET, BFPET, and VasoPET -- for the efficient detection and assessment of acute and chronic forms of co...


More From BioPortfolio on "Data Aquisition for Optimization of Coronary Artery Disease Algorithm"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks